FDA warned Entia Biosciences over mushroom supplement website claims that made the products unapproved, misbranded drugs.
What happened
FDA reviewed the company's website at www.totalnutraceutical.com in September 2020 and December 2020 and found product pages for six mushroom products with claims such as lowering cholesterol, anti-inflammatory effects, cancer fighting, and treating respiratory disease. FDA said these claims show the products are intended as drugs, but they are not FDA-approved and lack adequate directions for use.
What FDA found
Website claims that the mushroom products lower cholesterol, fight inflammation or cancer, or treat disease make them drugs intended to cure, mitigate, treat, or prevent disease.
FD&C Act section 201(g)(1)(B) [21 U.S.C. § 321(g)(1)(B)]The products are not generally recognized as safe and effective for those uses, so they are new drugs sold without required FDA approval.
FD&C Act sections 201(p), 301(d), and 505(a) [21 U.S.C. §§ 321(p), 331(d), 355(a)]The products lack adequate directions for safe lay use because the claimed diseases are not amenable to self-diagnosis or treatment without a licensed practitioner.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]; 21 CFR 201.5Selling these misbranded drugs in interstate commerce violates the Act.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]
What FDA wants
Within 15 working days of receipt, tell FDA in writing the specific steps taken to correct the violations, with documentation and steps to prevent recurrence. If the company believes the products are not violations, it must include its reasoning and supporting information; if corrections cannot be completed in that time, it must state the reason and completion date.
Who should pay attention
- dietary supplement brands selling mushroom products
- ecommerce teams writing product claims
- regulatory staff reviewing supplement labeling and websites
This is a summary. Read the original letter on fda.gov.